XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
ASSETS    
Cash and cash equivalents $ 19,509 $ 22,593
Marketable securities 16,347 27,942
Prepaid and other current assets 1,836 3,389
Total current assets 37,692 53,924
Property and equipment, net 96 175
Acquired license - intangible, net 210 263
Other assets 201 332
Total assets 38,199 54,694
Liabilities    
Accounts payable 556 2,421
Accrued liabilities 4,135 4,169
Total current liabilities 4,691 6,590
Other long-term liabilities 72 210
Total liabilities 4,763 6,800
Commitments and Contingencies (Note 13)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,320,338 and 8,150,635 shares at September 30, 2024 and December 31, 2023, respectively; and outstanding, 8,319,600 and 8,149,897 shares at September 30, 2024 and December 31, 2023, respectively 8 8
Additional paid-in capital 577,878 576,971
Treasury stock, at cost; 738 shares at September 30, 2024 and December 31, 2023 (708) (708)
Accumulated deficit (543,456) (528,081)
Accumulated other comprehensive loss (32) (42)
Total Lisata Therapeutics, Inc. stockholders' equity 33,690 48,148
Non-controlling interests (254) (254)
Total equity 33,436 47,894
Total liabilities, non-controlling interests and stockholders' equity $ 38,199 $ 54,694